Menora Mivtachim Holdings LTD. Purchases 61,039 Shares of MediWound Ltd. $MDWD

Menora Mivtachim Holdings LTD. increased its position in MediWound Ltd. (NASDAQ:MDWD) by 348.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 78,539 shares of the biopharmaceutical company’s stock after buying an additional 61,039 shares during the quarter. Menora Mivtachim Holdings LTD. owned 0.71% of MediWound worth $1,415,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Meitav Investment House Ltd. grew its holdings in MediWound by 825.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after acquiring an additional 260,116 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of MediWound during the third quarter valued at about $1,042,000. MGO One Seven LLC raised its stake in shares of MediWound by 82.6% during the third quarter. MGO One Seven LLC now owns 22,209 shares of the biopharmaceutical company’s stock valued at $400,000 after acquiring an additional 10,047 shares during the last quarter. Sheets Smith Investment Management purchased a new stake in shares of MediWound during the third quarter worth about $362,000. Finally, Silverberg Bernstein Capital Management LLC boosted its holdings in shares of MediWound by 17.1% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 172,816 shares of the biopharmaceutical company’s stock worth $3,114,000 after purchasing an additional 25,281 shares during the period. 46.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MDWD. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Finally, Wall Street Zen lowered MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $31.67.

MediWound Trading Down 3.7%

NASDAQ:MDWD opened at $16.58 on Friday. The company has a 50-day moving average price of $17.60 and a 200-day moving average price of $17.86. The stock has a market cap of $212.39 million, a price-to-earnings ratio of -7.90 and a beta of 0.13. MediWound Ltd. has a 12 month low of $14.14 and a 12 month high of $22.50.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.09. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. The company had revenue of $1.87 million for the quarter, compared to analysts’ expectations of $2.09 million. Equities analysts forecast that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.